# reload+after+2024-01-21 20:45:01.345567
address1§333 Lakeside Drive
city§Foster City
state§CA
zip§94404
country§United States
phone§650 574 3000
fax§650 522 5853
website§https://www.gilead.com
industry§Drug Manufacturers—General
sector§Healthcare
longBusinessSummary§Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
fullTimeEmployees§17000
companyOfficers§[{'maxAge': 1, 'name': "Mr. Daniel P.  O'Day", 'age': 59, 'title': 'Chairman & CEO', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 7267338, 'exercisedValue': 0, 'unexercisedValue': 9635551}, {'maxAge': 1, 'name': 'Mr. Andrew D. Dickinson', 'age': 53, 'title': 'Executive VP & CFO', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 2935112, 'exercisedValue': 0, 'unexercisedValue': 5436829}, {'maxAge': 1, 'name': 'Ms. Deborah H. Telman', 'age': 58, 'title': 'Executive VP of Corporate Affairs, General Counsel & Corporate Secretary', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 2323080, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Johanna  Mercier', 'age': 53, 'title': 'Chief Commercial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 3322200, 'exercisedValue': 0, 'unexercisedValue': 3864125}, {'maxAge': 1, 'name': 'Dr. Merdad V. Parsey M.D., Ph.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 3074714, 'exercisedValue': 0, 'unexercisedValue': 3047349}, {'maxAge': 1, 'name': 'Ms. Sandra  Patterson', 'age': 56, 'title': 'Senior VP, Corporate Controller & Principal Accounting Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jacquie  Ross C.F.A.', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jyoti K. Mehra', 'age': 47, 'title': 'Executive Vice President of Human Resources', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Linda Slanec Higgins Ph.D.', 'age': 61, 'title': 'Senior Vice President of Research, Innovation & Portfolio', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rudolf  Ertl', 'age': 77, 'title': 'Senior Vice President of Commercial Operations of Australia, Canada, Europe', 'yearBorn': 1946, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§4
compensationRisk§3
shareHolderRightsRisk§1
overallRisk§1
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§3.0
dividendYield§0.036
exDividendDate§1702512000
payoutRatio§0.6381
fiveYearAvgDividendYield§3.95
beta§0.254
priceToSalesTrailing12Months§3.7898433
currency§USD
dateShortInterest§1702598400
forwardEps§7.28
pegRatio§3.02
exchange§NMS
quoteType§EQUITY
shortName§Gilead Sciences, Inc.
longName§Gilead Sciences, Inc.
firstTradeDateEpochUtc§696090600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8659e669-8ec5-3b0f-9929-db5db506231f
gmtOffSetMilliseconds§-18000000
targetHighPrice§116.0
targetLowPrice§69.0
targetMeanPrice§89.29
targetMedianPrice§88.5
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§24
quickRatio§1.069
earningsGrowth§0.218
grossMargins§0.78810996
ebitdaMargins§0.42853
trailingPegRatio§0.5776
